NuCana plc (NCNA) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

Medium Risk
Moderate dilution risk
Last updated: March 19, 2026

Risk Assessment Details

Potential Dilution: 0.0% of current shares
Recent Dilution: 4120.33% (2 years)
Historical Dilution Factor: significant recent dilution
Outstanding Shares
21B
Potential Supply
0
Additional shares possible
Splits
None
Past 2 years

Summary

NCNA currently has 20.8B outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 4120.33% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
Mar 19, 2026

20-F filing | 20809.9M shares outstanding

21B 0
Apr 24, 2025

F-1 filing: NuCana PLC is offering up to 16,049,383 ADSs, Pre-Funded Warrants, Series A Warrants and Series B Warrants and intends to use the net proceeds of this offering, together with our existing cash and cash equivalents, to fund activities relating to the advancement of our drug discovery and development programs, and for other general corporate purposes.

550M 0
Mar 20, 2025

20-F filing | 142.0M shares outstanding

140M 5.8M
Aug 15, 2024

F-3 filing: The filing relates to a shelf registration for the potential issuance of up to $150,000,000 of any combination of American Depositary Shares representing Ordinary Shares, Debt Securities, Warrants, Rights, or Units.

53M 95M
Mar 20, 2024

20-F filing | 52.9M shares outstanding

53M 47M
Apr 04, 2023

20-F filing | 52.4M shares outstanding

52M 48M
Apr 27, 2022

20-F filing | 52.2M shares outstanding

52M 48M
Aug 19, 2021

F-3 filing: The filing is an F-3 type and describes a shelf offering that will allow the company to issue up to $400,000,000 of any combination of securities, including American Depositary Shares (ADSs) and debt securities. An 'at the market offering' of ADSs may be made from time to time through Jefferies LLC, with an aggregate offering price of up to $100.0 million. The company intends to use the net proceeds to fund drug discovery and development programs, and for other general corporate purposes.

52M 48M
Mar 04, 2021

20-F filing | 51.2M shares outstanding

51M 0
Mar 10, 2020

20-F filing | 32.5M shares outstanding

32M 0
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime